Physician profile
Modhi Gude
NPI 1346272523
$3,314.08
in general payments reported to CMS, 2019-2025
22 companies · $777 in 2025
The $777 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $994 · 2021: $409 · 2022: $291 · 2023: $18.65 · 2024: $29.34 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400 · Food and Beverage: $385 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
| Food and Beverage | $385.25 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,192.05 | 2019-2021 | |
| Lilly USA, LLC | $447.36 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Tandem Diabetes Care, INC. | $400.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $266.45 | 2020-2022 | |
| Novo Nordisk INC | $158.06 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.53 | 2019-2021 | |
| Abbvie INC. | $100.79 | 2019-2021 | |
| Antares Pharma, INC. | $98.03 | 2019-2025 | Xyosted |
| Amgen INC. | $82.66 | 2025 | Evenity, Tepezza |
| Madrigal Pharmaceuticals | $78.93 | 2025 | Rezdiffra |
| Chiesi USA, INC. | $56.22 | 2025 | Mycapssa |
| Corcept Therapeutics | $41.31 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $40.50 | 2019-2022 | |
| Dexcom, INC. | $37.51 | 2023-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $27.04 | 2025 | Isturisa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $25.60 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $23.06 | 2025 | Imcivree |
| Amarin Pharma, INC. | $22.19 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.74 | 2019 | |
| Shire North American Group INC | $20.95 | 2019 | |
| Ibsa Pharma INC. | $16.51 | 2019 | |
| Merck Sharp & Dohme LLC | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Modhi Gude listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.